cGAS-STING-agonist

cGAS-STING agonist (STING アゴニスト)

一行要約

細胞質 DNA センサー cGAS-STING 経路を pharmacologically に活性化し、type I IFN + 炎症性サイトカイン産生 → DC 成熟 → CD8+ T cell cross-priming → 抗腫瘍適応免疫を惹起する innate immune agonist class。Fu et al. SciTranslMed 2015 が CDN + GM-CSF ワクチン (STINGVAX) + anti-PD-1 で確立腫瘍の 100% 完全退縮を前臨床で実証し、「cold tumor → hot tumor」変換 + IO 増強 paradigm を確立した。臨床では腫瘍内投与型 (ADU-S100, MK-1454) の Phase I/II で単剤活性が限定的 (ORR 約10%) だったが、全身投与型 non-CDN agonist (MSA-2, diABZI) や next-gen STING agonist (dazostinag / TAK-676 / SNX281) が PK / therapeutic window 改善で再挑戦。STK11/LKB1 loss → STING epigenetic silencing (Kitajima et al. CancerDiscov 2019) は KRAS-LKB1 腫瘍の IO 耐性の分子基盤であり、STING 回復戦略 (DNMT 阻害 / EZH2 阻害) の治療標的。Campisi et al. CancerCell 2026 が SCLC での血管内皮 STING 活性化 → NK cell 浸潤回復を示し、non-tumor cell STING が immune trafficking の gatekeeper であることを実証。ENPP1 (cGAMP 分解酵素) 阻害と combination で活性持続化を図る戦略も開発中。

メンバー比較表

薬剤	化学型	投与経路	STING 結合型	開発段階	開発元	Key feature
ADU-S100 (MIW815)	CDN	腫瘍内注射	Cyclic dinucleotide (2’,3’-cGAMP analog)	Phase I/II → 中止	Novartis/Aduro	First clinical STING agonist; ORR 限定
MK-1454	CDN	腫瘍内注射	CDN (proprietary)	Phase I/II + Pembrolizumab	Merck	IO combination; HNSCC で partial response
MSA-2	Non-CDN	経口	Non-nucleotide small molecule	Phase I	—	初の全身投与可能 non-CDN
diABZI	Non-CDN	全身投与 (前臨床)	Amidobenzimidazole dimer	前臨床	GSK	強力; マウスで high efficacy
Dazostinag (TAK-676)	Non-CDN	IV systemic	Non-CDN	Phase I/II	Takeda	Systemic IV; IO combination
SNX281	Non-CDN	経口	Small molecule	Phase I	Stingthera	Oral bioavailability
DMXAA	Flavonoid	—	Flavone analog	開発中止	—	マウス STING のみ活性化、ヒト不活性 — species selectivity の教訓
ML-RR-S2-CDA	Synthetic CDN	皮下 (ワクチン)	Modified CDN (Rp,Rp-dithio, mixed linkage)	前臨床	Aduro	全ヒト STING allele (WT/HAQ) に活性

主要エビデンス

前臨床 paradigm: STINGVAX + PD-1 blockade

• Fu et al. SciTranslMed 2015: CDN を GM-CSF 全細胞ワクチンに組み込んだ STINGVAX が B16 / CT26 / SCCFVII / Panc02 確立腫瘍で STING 依存的・CD8+ T cell 依存的抗腫瘍効果を示した。ML-RR-S2-CDA (合成 CDN) が 全ヒト STING allele 型 (WT / HAQ) を活性化。STINGVAX + anti-PD-1 で CT26 確立腫瘍 10/10 例完全退縮 (100%) + 長期免疫記憶形成。PD-1 単独では効果なし → STING agonist が PD-L1 を誘導 (adaptive resistance) し、その状態で PD-1 blocking が CTL を解放する synergy 機構
• Key insight: STING agonist → tumor-intrinsic IFN → PD-L1 upregulation → PD-1 blocking の標的化 → IO synergy という合理的 combination 根拠を明示

臨床 Phase I/II: ADU-S100 + Spartalizumab

• Meric-Bernstam JCO 2022: ADU-S100 IT 投与 + anti-PD-1 (spartalizumab)。Multiple solid tumors で ORR 約10%。Inject lesion での partial response は観察されたが non-inject lesion の discordant response → abscopal 効果は不十分
• 失敗の教訓: (1) IT 投与の全身 immune priming 能の限界、(2) 短い半減期 (CDN は rapid degradation by ENPP1)、(3) 投与可能病変の制限 (深部臓器アクセス不可)、(4) Optimal dose / schedule 未確立

臨床 Phase I/II: MK-1454 + Pembrolizumab

• Chang et al. NatBiotechnol 2022: MK-1454 IT + pembrolizumab。HNSCC / melanoma で partial response 観察。ORR は ADU-S100 よりやや改善だが、やはり IT 投与の systemic efficacy limitation が issue

全身投与型 non-CDN STING agonist (MSA-2 / diABZI)

• MSA-2 (Pan Science 2020) : Non-CDN small molecule STING agonist。経口投与可能。マウスで用量依存的腫瘍退縮 + memory immunity 形成。全身投与により IT 投与の accessibility limitation を克服
• diABZI: Amidobenzimidazole dimer。IV / IP 投与でマウス CT26 model に potent activity。STING binding affinity が CDN の 10 倍以上。Systemic delivery でも therapeutic window あり → next-gen clinical candidate の prototype
• Dazostinag (TAK-676) : IV systemic STING agonist。Phase I/II で IO combination を評価中。Campisi et al. CancerCell 2026 が dazostinag + anti-PD-1 の前臨床 SCLC model で NK cell mediated anti-tumor immunity を実証

STK11/LKB1 loss と STING silencing

• Kitajima et al. CancerDiscov 2019: KRAS-LKB1 (KL) 変異 NSCLC で LKB1 喪失 → SAM 蓄積 → DNMT1 / EZH2 過活性化 → STING プロモーター DNA methylation + H3K27me3 → STING 完全サイレンシング → 細胞質 dsDNA sensing 不全 → IFNβ / CXCL10 分泌消失 → T cell 除外 / PD-L1 低発現 → ICB 耐性の分子基盤
• STING 回復戦略: DAC (DNMT 阻害) + GSK126 (EZH2 阻害) で STING 発現回復 → dsDNA 刺激後の IFNβ / CXCL10 分泌回復 → T cell 浸潤改善。「Epigenetic STING reactivation + IO」の combination 根拠
• mtDNA leakage as STING silencing pressure: KL 細胞は mitochondrial DNA の細胞質漏出が亢進 → STING 強制発現で autotoxicity → STING サイレンシングが生存に必須 (選択的エピジェネティック抑制)。この機構は外因性 STING agonist が KL 腫瘍で無効である根拠 (tumor cell 自体の STING は absent)

血管内皮 STING と NK cell 浸潤

• Campisi et al. CancerCell 2026: NE MHC-I^low SCLC は NK cell 傷害性に in vitro 高感受性だが in vivo では NK 排除。空間解析 + 3D MITE model で 腫瘍血管内皮の STING 活性化 が VCAM1 / E-selectin / CXCL10 を誘導し NK cell の血管外漏出を回復させることを実証
• Non-tumor cell STING の重要性: 腫瘍��胞自体の STING は epigenetically silenced (特に NE tumors) だが、内皮細胞 / 線維芽細胞 / マクロファージの STING は intact → exogenous STING agonist は stroma STING を activate して immune trafficking を回復
• DLL3 CAR-NK との synergy: ADU-S100 IT + DLL3 CAR-NK の combination で vascularized xenograft model にて enhanced anti-tumor activity → STING agonist が CAR-NK のアクセス barrier (vascular) を解除する戦略

Radiation + STING (内因性 agonism)

• 放射線照射 → 腫瘍細胞の DNA 二重鎖切断 → micronuclei 形成 → micronuclei 膜破裂 → 細胞質 dsDNA 露出 → cGAS 活性化 → 内因性 2’,3’-cGAMP 産生 → STING activation → type I IFN → abscopal 効果の一因
• IO + radiation synergy の分子基盤: STING pathway が radiation-induced immunogenic cell death と IO の bridge。STING-silenced tumor (KL subtype) は radiation + IO でも benefit 少ない予測

ENPP1 と cGAMP 分解

• ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) : Cell surface / extracellular enzyme が cGAMP を rapid に hydrolysis → STING agonism の duration を制限
• ENPP1 inhibitor + STING agonist combination: cGAMP 半減期延長 → sustained STING activation → enhanced DC maturation / T cell priming
• 次世代 CDN design: ENPP1-resistant CDN (phosphorothioate modification: RR-S2 CDA, ML-RR-S2-CDA) で enzymatic degradation を回避 (Fu et al. SciTranslMed 2015)

メカニズム

cGAS-STING 経路の生物学

Canonical pathway:

1. cGAS activation: 細胞質に dsDNA が出現 (腫瘍由来 / radiation 由来 / ウイルス由来 / mtDNA leakage) → cyclic GMP-AMP synthase (cGAS) が dsDNA に直接結合 → 活性化
2. cGAMP synthesis: Active cGAS が ATP + GTP から 2’,3’-cGAMP (second messenger) を合成
3. STING activation: cGAMP が ER 膜上の STING (TMEM173) に結合 → STING dimer の conformational change → ER → Golgi trafficking
4. TBK1 recruitment: STING が TBK1 (TANK-binding kinase 1) を recruit → TBK1 autophosphorylation
5. IRF3 activation: pTBK1 → IRF3 リン酸化 → IRF3 dimerization → 核移行 → type I IFN (IFNα/β) 転写
6. NF-κB co-activation: STING → NF-κB pathway → pro-inflammatory cytokines (TNFα, IL-6, CXCL10)

STING の初同定: Ishikawa et al. Nature 2009 が Sting KO マウスで細胞内 DNA mediated type I IFN 産生における STING の必須性を初めて実証 — HSV-1 / adenovirus / bacterial DNA 全てに対する防御に STING が required

Innate-Adaptive Immune Bridge

STING activation の downstream immune cascade:

1. Type I IFN 産生 → autocrine / paracrine signaling
2. DC maturation: IFNα/β → DC の MHC-I/II upregulation + co-stimulatory molecule (CD80/86) upregulation + cross-presentation 能力増強
3. Cross-priming: Mature DC が tumor antigen を CD8+ T cell に cross-present → tumor-specific CTL の priming / expansion
4. CXCL9/10 induction: → CXCR3+ effector T cell / NK cell の腫瘍浸潤促進
5. TME remodeling: MDSC / M2-TAM の M1 repolarization、NK 細胞活性化、endothelial VCAM1 upregulation → T/NK cell trafficking 増強

Pharmacological STING Agonism の分類

CDN (Cyclic Dinucleotide) 型:

• Natural ligand (2’,3’-cGAMP) の analog
• STING binding site に直接 engage
• 問題: (1) ENPP1 による rapid degradation、(2) 大きな分子量 → oral bioavailability なし、(3) IT 投与限定

Non-CDN small molecule 型:

• STING の palmitoylation site / allosteric site に結合
• 利点: oral bioavailability / systemic delivery / ENPP1-resistant
• MSA-2, diABZI, dazostinag, SNX281 等

Indirect STING activation 戦略:

• ENPP1 inhibitor → endogenous cGAMP preservation
• PARP inhibitor → DNA damage → cGAS activation → endogenous STING agonism
• Radiation → micronuclei → cGAS → endogenous pathway

ヒト STING Allele 多型

STING (TMEM173) には functional SNP が存在:

• WT (R232) : 人口の 約60%。Standard CDN に反応
• HAQ��R71H-G230A-R293Q): 人口の 約20%。Standard 3’,3’-CDN に低感受性 → ML-RR-S2-CDA が全 allele 型���活性化 (Fu et al. SciTranslMed 2015)
• REF (R232H) : 人��の 約15%。cGAMP 反応性一部低下
• 臨床的意義: CDN 型 STING agonist は allele-dependent な efficacy variability → non-CDN 型は allele 非依存的 binding で universal efficacy 期待

全身毒性 / Therapeutic Window の課題

• Systemic type I IFN syndrome: High-dose systemic STING agonist → IFN storm / cytokine release → autoimmune-like toxicity。IL-6 / TNFα の systemic burst が sepsis-like picture
• Therapeutic window: IT 投与は全身毒性を回避するが systemic immunity 不十分 → systemic 投与は全身 priming だが toxicity → 用量最適化 / 腫瘍選択的 delivery / prodrug approach が解決策
• EV (extracellular vesicle) delivery: cGAMP を tumor-homing EV に搭載 → 腫瘍選択的 STING activation の前臨床コンセプト
• 次世代 non-CDN の改善点: Lower maximum Emax + wider dose range → flat dose-response curve で toxicity 回避しつつ efficacy 維持

STING Silencing と Cancer Type 適性

Cancer type	STING status (tumor)	Stroma STING	STING agonist 適性
KRAS-TP53 (KP) NSCLC	発現あり	◎	◎ — tumor + stroma both respond
KRAS-LKB1 (KL) NSCLC	Silenced	◎	△ — stroma only; tumor-intrinsic pathway dead
SCLC (NE subtype)	Low/absent	◎ (endothelial)	△ — endothelial STING → NK trafficking
MSI-H / DDR-deficient	高発現 (DNA damage → cGAS active)	◎	◎ — amplify endogenous pathway
Melanoma	Variable	���	◎ — Woo Immunity 2014 で STING-dependent tumor sensing 実証

臨床位置づけ

Current Clinical Landscape (2026)

設定	Agent	Status	結果
IT + anti-PD-1 (solid tumors)	ADU-S100 + spartalizumab	Phase I/II → 中止	ORR 約10%, abscopal 不十分
IT + pembrolizumab (HNSCC/melanoma)	MK-1454 + pembro	Phase II	Partial response 観察
Systemic + IO (solid tumors)	Dazostinag (TAK-676) + IO	Phase I/II ongoing	前臨床 strong signal
Oral (solid tumors)	MSA-2	Phase I	Dose escalation 中
Oral (solid tumors)	SNX281	Phase I	Dose escalation 中

治療戦略と Patient Selection

STING agonist が有効な patient population (推定) :

• STING-intact stroma + tumor: KRAS-TP53 NSCLC / MSI-H / DDR-deficient tumors — endogenous cGAS pathway の amplification で IO synergy 最大化
• IO 単剤 non-responder で TME が “cold”: Low TIL / low PD-L1 → STING agonist で type I IFN → DC maturation → TIL infiltration → IO sensitization (Fu et al. SciTranslMed 2015 の paradigm)
• SCLC (endothelial STING 活性化) : Campisi et al. CancerCell 2026 に基づき、STING agonist → NK trafficking → DLL3 CAR-NK / BiTE との sequential combination

STING agonist が無効 / 注意すべき population:

• KRAS-LKB1 (KL) : Tumor STING 完全サイレンシング → tumor-intrinsic IFN 誘導不可 (Kitajima et al. CancerDiscov 2019)。Stroma STING activation のみで十分か不明 → DNMT/EZH2 阻害との prior combination が理論的に必要
• Autoimmune-prone patients: Systemic type I IFN → autoimmune flare リスク

Combination Strategies

Combination	Rationale	Evidence
STING + anti-PD-1/PD-L1	STING → PD-L1 upregulation → PD-1 blocking target 化	STINGVAX + PD-1 で CT26 100% CR
STING + anti-CTLA-4	Innate priming + adaptive checkpoint release	前臨床 synergy
STING + radiation	Radiation → endogenous cGAS → STING amplification	Abscopal 効果増強
STING + PARP inhibitor	PARP-i → DNA damage → cGAS → endogenous STING	DDR-proficient tumor を DDR-deficient mimic に
STING + ENPP1 inhibitor	cGAMP degradation 阻止 → sustained STING activation	前臨床
STING + CAR-NK	Vascular STING → NK trafficking barrier 解除	Campisi CancerCell 2026
STING + DNMT/EZH2 inhibitor	KL tumor の STING epigenetic recovery	Kitajima CancerDiscov 2019

Open Questions

• Systemic STING agonist の therapeutic window: MSA-2 / dazostinag 等 non-CDN agonist の Phase I/II dose-response と systemic cytokine toxicity の balance。Optimal dose / schedule / patient population の定義
• Biomarker for patient selection: Tumor / stroma STING expression level (IHC? RNA?) / cGAS pathway integrity / STK11 status → response prediction。STING-silenced (KL subtype) の exclusion vs epigenetic recovery 後の re-sensitization
• ENPP1 inhibitor との combination timing: ENPP1-i → cGAMP preservation の臨床試験 design。Toxicity concern (cGAMP persistence → prolonged IFN → autoimmunity?)
• Cancer type 最適選択: MSI-H / DNA repair-deficient 腫瘍 (内因性 cytosolic DNA 豊富 → cGAS already active → external agonist の add-on 意義) vs low-TMB cold tumor (external agonist で de novo IFN induction) のどちらが optimal target か
• STING + PARP + IO triple: DDR 阻害 → DNA damage → cGAS activation → STING → IO の triple combination の feasibility / overlapping toxicity。DDR-proficient NSCLC / ovarian cancer での proof
• EV / nanoparticle delivery: cGAMP / STING agonist を tumor-homing vehicle に搭載する selective delivery — systemic toxicity 回避 + IT の accessibility limitation 克服
• Radiation + STING agonist: Already active endogenous pathway を exogenous agonist で boost → RT + STING + IO triple の optimal scheduling (neoadjuvant? concurrent?)
• STK11 復活戦略の臨床実装: DAC + EZH2-i → STING recovery は前臨床 proven。Clinical translation (epigenetic drugs の dose / duration / STING recovery monitoring) の feasibility

重要論文 Top 10

1. ★★★★★ Ishikawa et al. Nature 2009 — STING の同定 — 経路全体の分子基盤を確立
2. ★★★★★ Fu et al. SciTranslMed 2015 — STINGVAX + PD-1 — 確立腫瘍 100% CR の前臨床 proof
3. ★★★★★ Kitajima et al. CancerDiscov 2019 — STK11 loss → STING silencing — KL 腫瘍の IO 耐性分子基盤
4. ★★★★★ Campisi et al. CancerCell 2026 — 血管内皮 STING → NK trafficking — non-tumor STING の重要性
5. Pan et al. — MSA-2 — Non-CDN systemic STING agonist — oral / systemic delivery の突破口

関連エンティティ・概念

• 関連 class: PD-1-inhibitor (IO 増強 partner), CTLA-4-inhibitor (innate + adaptive bridge), PARP-inhibitor (DDR → cGAS 活性化)
• 関連遺伝子 / pathway: STK11 (LKB1 loss → STING silencing), KRAS (KL subtype context), EZH2 (STING epigenetic suppression)
• 概念: NETosis (NET 由来 DNA → cGAS trigger), Pre-metastatic-niche (STING と転移前 niche 形成), KRAS co-mutation landscape (KL vs KP の免疫 phenotype 差異)
• 関連 drug: DLL3-targeted-therapy (SCLC での STING + CAR-NK combination)
• ドメイン: novel-cancer-modalities, cancer-biology, lung-cancer-biology

関連論文

直近 30 件のみ表示中 (関連 37 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Liu et al. CancerPathogTher 2024 — Experimental models for cancer brain metastasis
• Faust et al. NatImmunol 2026 — Astrocyte-driven immunosuppression in the brain tumor microenvironment
• Achrol et al. NatRevDisPrimers 2019 — Brain metastases
• Chafe et al. SciSignal 2026 — Emerging paradigms in the study of brain metastases

Basic-Extracellular vesicles

• Allen et al. FrontImmunol 2022 — Extracellular vesicles from A23187-treated neutrophils cause cGAS-STING-dependent IL-6 production by macrophages
• Lee et al. JExtracellVesicles 2026 — Systemic propagation of STING signalling via generation of large extracellular vesicles
• Arvanitaki et al. ProcNatlAcadSciUSA 2024 — Microglia-derived extracellular vesicles trigger age-related neurodegeneration upon DNA damage

Basic-Immunotherapy

• Kitajima et al. CancerCell 2022 — MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
• Kureshi et al. CancerCell 2026 — Dendritic cell redundancy enables priming of anti-tumor cd4+ t cells in pancreatic cancer
• Mahadevan et al. CancerDiscov 2021 — Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity
• Burger et al. Cell 2021 — Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors
• Marzio et al. Cell 2022 — EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion
• Patel et al. Immunity 2018 — Combination cancer therapy with immune checkpoint blockade mechanisms and strategies
• Beltra et al. Immunity 2020 — Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic
• Meric-Bernstam et al. Lancet 2021 — Enhancing anti-tumour efficacy with immunotherapy combinations
• Feng et al. NatRevCancer 2019 — Phagocytosis checkpoints as new targets for cancer immunotherapy
• Lu et al. NatRevCancer 2026 — Opportunities and challenges of targeting cGAS-STING in cancer
• Haag et al. Nature 2018 — Targeting STING with covalent small-molecule inhibitors
• Zhou et al. Science 2026 — Intermetallic nanoassemblies potentiate systemic STING activation

Basic-Oncogene and genetics

• Ghosh et al. CancerCell 2021 — Mutant p53 suppresses innate immune signaling to promote tumorigenesis
• Sui et al. CellDeathDiscov 2025 — Lactylation in cancer metabolic mechanism and therapeutic strategies
• Bakhoum et al. Nature 2018 — Chromosomal instability drives metastasis through a cytosolic DNA response
• Li et al. Nature 2023 — Non-cell-autonomous cancer progression from chromosomal instability

Basic-Others

• Zhang et al. MolCell 2026 — PKCalpha-mediated nuclear translocation of cGAS stabilizes beta-catenin and drives metastasis
• Zhang et al. Nature 2026 — The mutational landscape of STING-induced immunity
• Chen et al. iScience 2024 — Translating CD47-targeted therapy in gastrointestinal cancers insights from preclinical to clinical studies

Basic-Tumor microenvironment

• Martin et al. NatRevClinOncol 2020 — Improving cancer immunotherapy using nanomedicines progress, opportunities and challenges

Clinical-Others

• Chadwick et al. NatRevCancer 2026 — Striking the right balance with type i interferon signalling in cancer

Clinical-Respiratory diseases

• Velu et al. JClinInvest 2026 — Interstitial lung disease and the STING pathway

Clinical-SCLC

• Campisi et al. CancerCell 2026 — Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

合成 (Outputs)

• adc-payload-diversity-ild-management
• kl-mutant-io-resistance-combination
• kras-g12d-druggability-io-resistance